Lumicell is changing the landscape of cancer surgery with a hand-held imaging system that enables surgeons to identify any cancer cells left behind on the tumor cavity walls and take action in real-time to improve patient outcomes.
Lumicell is addressing the number one challenge in cancer surgery – the need to remove all cancer cells during the first surgery while preserving healthy tissue.
Lumicell Presents Phase 2 Clinical Data Showing LUM System Provided Complete and Immediate Detection of Residual Cancer in Tumor Cavity During Lumpectomy Surgery--
Data Presented by Investigators from Massachusetts General Hospital's Breast Program at 2017 San Antonio Breast Cancer Symposium Integrated LUM System Correctly Identified Residual Cancer Cells Across Breast Cancer Subtypes
Lumicell Expands Development Strategy and Pipeline Across Five Solid Tumor Cancers Supported by $28.7 Million Series C Financing--
Proceeds to Fund Pivotal Trial in Breast Cancer Leverages Broad Potential of LUM System with Drug, Device and Software for Real-time Detection of Tumor Tissue in Patients During Surgery
LUM Imaging System to Detect Residual Cancer During Surgery to Start Advanced Clinical Trial --
A possibly pivotal clinical trial using an imaging technology – the LUM Imaging System by Lumicell — to detect residual tumor tissue in breast cancer patients undergoing surgery is in the planning stages, the company announced after the U.S. Food and Drug Administration (FDA) approved the system’s use in a new study.
Lumicell Initiates New Clinical Studies in Breast Cancer and Prostate Cancer with LUM System for Real-time Detection of Tumor Tissue in Patients During Surgery
Lumicell Initiates New Clinical Studies in Breast Cancer and Prostate Cancer with LUM System for Real-time Detection of Tumor Tissue in Patients During Surgery -- Company receives FDA Approval to initiate multiple IDE studies, Including Path to Pivotal Trial in Breast Cancer. Integrated LUM System with Drug, Device and Software Currently Under Investigation in Five Solid Tumor Cancers
Lumicell to Participate in Upcoming Conferences -- Lumicell announced their presence at the 2nd International Prostate Cancer Symposium & Inagugural World Congress of Urologic Oncology. Felix Geissler, MD, PhD and CMO will be on-site at the Lumicell exhibit booth. Kelly Londy, CEO will be present as a guest faculty member at the Institute for Biomedical Entrepreneurship (IBE) Certificate Session being held in Cambridge, MA.
Lumicell Announces Product Development Progress with LUM015 in Lumicell System for Image-guided Cancer Surgery -- Lumicell announced the company’s progress with its product development of the Lumicell System, as well as the expansion of patent protection for the company’s product and technologies. The foundation of Lumicell’s product development plan is the integration of three proprietary components: the immuno- and cancer-targeted optical contrast agent LUM015, the Lumicell handheld imaging device, and the company’s customized software for real-time display.